Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study

Table 1 Demographic characteristics of patients with combined hepatocellular-cholangiocarcinoma before radical resection

	Overall	The 5th Medical Center of the PLA General Hospital	Peking Union Medical College Hospital	P value
Number	98	34	64
Age, mean ± SD	55.3 (10.4)	53.5 (10.4)	56.3 (10.3)	0.219
Sex
Male	86 (87.8)	32 (88.2)	56 (87.5)	1 (Fisher)
Female (%)	12 (12.2)	4 (11.8)	8 (12.5)
ECOG (%)				0.009 (Fisher)
0	84 (85.7)	26 (76.5)	58 (90.6)
1	11 (11.2)	8 (23.5)	3 (4.7)
NA	3 (3.1)	0 (0)	3 (4.7)
Child-Pugh class				0.435 (Fisher)
A	86 (87.8)	32 (94.1)	54 (84.4)
B	6 (6.1)	1 (2.9)	5 (7.8)
NA	6 (6.1)	1 (2.9)	5 (7.8)
Liver disease (%)				0.823 (Fisher)
NA	4 (4.1)	1 (2.9)	3 (4.7)
HBV	81 (82.7)	28 (82.4)	53 (82.8)
HCV	4 (4.1)	2 (5.9)	2 (3.1)
Fatty liver	2 (2.0)	0 (0.0)	2 (3.1)
Alcohol	7 (7.1)	3 (8.8)	4 (6.2)
Gallstones (%)	13 (13.3)	3 (8.8)	10 (15.6)	0.533 (Fisher)
CA19-9 (U/mL)	26.5 [13.1, 56.2]	29.7 [15.1, 46.5]	23.6 [12.4, 56.4]	0.775 (non-norm)
< 37	58 (59.2)	21 (61.8)	37 (57.8)	0.813 (Fisher)
≥ 37	31 (31.6)	11 (32.4)	20 (31.2)
NA	9 (9.2)	2 (5.9)	7 (10.9)
AFP (ng/mL)	44.1 [7.0, 338.4]	43.4 [5.8, 294.7]	44.1 [7.8, 724.3]	0.389 (non-norm)
< 200	61 (62.2)	24 (70.6)	37 (57.8)	0.122 (Fisher)
≥ 200	30 (30.6)	10 (29.4)	20 (31.2)
NA	7 (7.1)	0 (0.0)	7 (10.9)
CEA (ng/mL)	2.7 [1.6, 4.4]	2.5 [1.5, 3.5]	2.7 [1.7, 4.8]	0.173 (non-norm)
< 6	80 (81.6)	32 (94.1)	48 (75.0)	0.038 (Fisher)
≥ 6	9 (9.2)	0 (0.0)	9 (14.1)
NA	9 (9.2)	2 (5.9)	7 (10.9)
TBil (μmol/L)	12.6 [10.4, 16.4]	12.2 [10.4, 14.0]	12.9 [10.7, 17.8]	0.260 (non-norm)
DBil (μmol/L)	4.3 [3.8, 5.7]	4.2 [3.8, 5.0]	4.5 [3.8, 5.8]	0.334 (non-norm)
Albumin (g/L)	41.0 [39.0, 43.5]	40.0 [38.0, 42.0]	41.0 [39.0, 44.0]	0.055 (non-norm)
Ascites (%)				0.094 (Fisher)
No	75 (76.5)	30 (88.2)	45 (70.3)
Yes	18 (18.4)	4 (11.8)	14 (21.9)
NA	5 (5.1)	0 (0.0)	5 (7.8)
Liver cirrhosis (%)	82 (83.7)	32 (94.1)	50 (78.1)	0.143 (Fisher)

ECOG: Eastern Cooperative Oncology Group; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: Alpha fetoprotein; CEA: Carcinoembryonic antigen; TBil: Total bilirubin; DBil: Direct bilirubin; NA: Not available.

Table 2 Clinicopathological characteristics of patients with combined hepatocellular cholangiocarcinoma

Item	Patients (n = 98)
Tumor number
Solitary	55 (56.1)
Multiple	39 (39.8)
NA	4 (4.1)
Tumor size, median [IQR]	4.5 [2.9, 6.5]
≤ 3cm (%)	26 (26.5)
3-5 cm (%)	36 (36.7)
> 5 cm (%)	34 (34.7)
NA	2 (2.0)
Resection margin (%)
≤ 1cm (%)	54 (55.1)
> 1cm (%)	21 (21.4)
NA	23 (23.5)
Macro VI (%)	24 (24.5)
Micro VI (%)	62 (63.3)
Lymph node metastasis (%)	12 (12.2)
TNM Stage (AJCC 8th) (%)
I	18 (18.4)
II	59 (60.2)
III	19 (19.4)
NA	2 (2.0)
Ki-67 (%)
≤ 50%	36 (55.4)
> 50%	29 (44.6)
CK7 (%)
Negative	9 (11.1)
Weak positive	29 (35.8)
Strong Positive	43 (53.1)
CK19 (%)
Negative	9 (10.8)
Weak positive	27 (32.5)
Strong Positive	47 (56.6)
HepPar-1 (%)
Negative	29 (34.1)
Weak positive	23 (27.1)
Strong Positive	33 (38.8)
GPC-3 (%)
Negative	16 (28.6)
Weak positive	13 (23.2)
Strong Positive	27 (48.2)
HCC differentiation (%)
Poorly differentiated	19 (41.3)
Well or moderate differentiated	27 (58.7)
ICC differentiation (%)
Poorly differentiated	30 (65.2)
Well or moderate differentiated	16 (34.8)
ICC percent (%)
≤ 50%	11 (30.7)
> 50%	16 (59.3)

Macro VI: Macrovascular invasion; Micro VI: Microvascular invasion; AJCC: American Joint Committee on Cancer; CK7: Cytokeratin 7; CK19: Cytokeratin 19; HepPar-1: Hepatocyte paraffin 1; GPC-3: Glypican-3; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma; NA: Not available.